Publications

Koirala A, Winkler N, Sharpe C, van Tussenbroek T, Wood P, Macartney K, Quinn H. Real-world utilisation of SARS-CoV-2 rapid antigen testing to enable face-to-face learning in Australian schools, an ecological study. Australian and New Zealand Journal of Public Health 2024;48:100159. doi: 10.1016/j.anzjph.2024.100159. [Full text]

Villanueva P, Crawford NW, Croda MG, Croda J, Dalcolmo M, Jardim BA, Jardim TAP, Marshall H, Prat-Aymerich C, Sawka A, Sharma K, Troeman D, Warris A, Wood N, Messina NL, Pittet LF, Curtis N. Accelerated Bacille Calmette-Guérin reactions: more than meets the eye. Heliyon 2024;10:e32510. doi: 10.1016/j.heliyon.2024.e32510. [Full text]

Shearer FM, Edwards L, Kirk M, Eales O, Golding N, Hassall J, Liu B, Lydeamore M, Miller C, Moss R, Price DJ, Ryan GE, Sullivan S, Tobin R, Ward K, Kaldor J, Cheng AC, Wood J, McCaw JM. Opportunities to strengthen respiratory virus surveillance systems in Australia: lessons learned from the COVID-19 response. Communicable Diseases Intelligence (2018) 2024;48. doi: 10.33321/cdi.2024.48.47. [Full text]

Sonneveld N, Jackson J, Dey A, Lambert SB, Clark KK, Cowie BC, Macartney K, Beard F. Australian vaccine preventable disease epidemiological review series: Hepatitis B, 2000-2019. Communicable Diseases Intelligence (2018) 2024;48. doi: 10.33321/cdi.2024.48.44. [Full text]

van der Kooi S, Beard F, Dey A, McIntyre P, Imai C, Amin J. Pertussis notifications decline in Australia during COVID-19 non-pharmaceutical interventions, 2020-2021. Communicable Diseases Intelligence (2018) 2024;48. doi: 10.33321/cdi.2024.48.24. [Abstract]

Glover C, Deng L, Larter C, Brogan C, Richardson O, Huang YA, Kay E, Macartney K, Wood N. Surveillance of adverse events following immunisation in Australia, COVID-19 vaccines, 2021. Communicable Diseases Intelligence (2018) 2024;48. doi: 10.33321/cdi.2024.48.2. [Full text]

Glover C, Deng L, Larter C, Brogan C, Richardson O, Huang YA, Kay E, Macartney K, Wood N. Surveillance of adverse events following immunisation in Australia annual report, 2021. Communicable Diseases Intelligence (2018) 2024;48. doi: 10.33321/cdi.2024.48.1. [Full text]

Imai C, Jayasinghe S, McRae J, Li-Kim-Moy J, Chiu C, Macartney K, Burns P, Cooper K, Cheng AC, Gibney K, Giles M, Jones C, Korman T, Liu B, Crawford NW; Australian Technical Advisory Group on Immunisation (ATAGI). Surveillance of adverse events following immunisation in Australia annual report, 2021.. Communicable Diseases Intelligence (2018) 2024;48. doi: 10.33321/cdi.2024.48.25. [Full text]

Kandasamy R, Gurung M, Shrestha S, Gautam MC, Kelly S, Thorson S, Ansari I, Gould K, Hinds J, Kelly DF, Murdoch DR, Pollard AJ, Shrestha S. Decline in pneumococcal vaccine serotype carriage, multiple-serotype carriage, and carriage density in Nepalese children after PCV10 introduction: a pre-post comparison study. Vaccine 2024:S0264-410X(24)00564-4. doi: 10.1016/j.vaccine.2024.05.018 . [Full text]

Marsland MJ, Thomson TN, O'Brien HM, Peach E, Bellette J, Humphreys N, McKeon CA, Cross W, Moso MA, Batty M, Nicholson S, Karapanagiotidis T, Lim CK, Williamson DA, Winkler N, Koirala A, Macartney K, Glynn-Robinson A, Stewart T, Minko C, Snow KJ, Black J, Friedman ND. Serosurvey for Japanese encephalitis virus antibodies following an outbreak in an immunologically naïve population, Victoria, 2022: a cross-sectional study. Medical Journal of Australia 2024. doi: 10.5694/mja2.52344 . [Full text]